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Available online 2 November 2005Abstract—We investigated the A3AR aﬃnity and selectivity of a series of 2-substituted 3
0-azido and 3 0-amino adenosine derivatives
as well as some 5 0-uronamide derivatives thereof. All compounds showed high A3AR selectivity. While the 3 0-azides appeared to be
A3AR antagonists with moderate A3AR aﬃnity, their 3
0-amino congeners exhibit signiﬁcantly improved A3AR aﬃnity and behave
as partial agonists. For both the 3 0-azides and the 3 0-amines, the 5 0-methylcarbamoyl modiﬁcation improved the overall aﬃnity.
Introduction of a 2-phenylethynyl substituent provided high aﬃnity for the A3AR.
 2005 Elsevier Ltd. All rights reserved.1. Introduction
Adenosine receptors (AR) belong to the family of G
protein-coupled receptors. They are subdivided into
four subtypes designated A1, A2A, A2B and A3, accord-
ing to the chronological discovery of the receptors.1 The
A3ARs are coupled to Gi proteins and, therefore, inhibit
adenylate cyclase leading to a decrease in intracellular
levels of cAMP.2 The selective activation of the A3AR
is both cardioprotective and cerebroprotective in a vari-
ety of ischaemic models.3,4 Selective A3AR antagonists
promise to be useful in the regulation of cell growth5,6
and as anti-asthmatic,7 cerebroprotective4,8 and anti-
inﬂammatory agents.9 A3AR antagonists appear to low-
er the intraocular pressure in mice and monkeys and are
proposed as new potential therapeutics for the treatment
of glaucoma.10,11
Adenosine receptors are ubiquitously distributed
throughout the body. As a consequence, ligands need
to be highly selective in their action with respect to0968-0896/$ - see front matter  2005 Elsevier Ltd. All rights reserved.
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Numerous structure–activity studies of adenosine deri-
vatives as receptor agonists conclude that selectivity
may be provided by speciﬁc substitutions of the adenine
ring.13,1 Substitution at the 8-position of the ring is not
well tolerated by any AR subtype.14,15 The nitrogen
atoms at positions 3 and 7 are required for high aﬃnity
of adenosine at all subtypes.1 2-Alkynyl derivatives of
NECA possess high aﬃnity at the A3 receptor subtype.
Moreover, the presence of 2-alkyne substituents en-
hanced the A3AR selectivity.
16
DeNinno et al. discovered that introduction of an amino
group at the 3 0 position improves the selectivity for the
human A3AR, while enhancing the water solubility.
The aﬃnity drop caused by this 3 0-substitution could
be overcome by elaborating the N6-substituents.17 The
combination of a large N6-substitituent with a 2-alkynyl
group has proven to be unsuccessful because of the ste-
ric hindrance caused by the two large substituents,
reﬂected by a decrease in A3AR aﬃnity.
16 Therefore,
the present study investigated the eﬀect of a 2-alkynyl
substituent in concert with a small N6-substituent on
the aﬃnity and selectivity of a series of 3 0-azido and
3 0-amino adenosine derivatives. In addition, we evaluat-
ed the eﬀect of the 5 0-methylcarbamoyl modiﬁcation on
the overall aﬃnity and eﬃcacy of these compounds
(Fig. 1).
Figure 1.
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2.1. Chemistry
3-Azido-3-deoxy-1,2-di-O-acetyl-a-D-ribofuronamide (10)
was prepared from the commercially available 1,2-O-
isopropylidene-a-D-xylofuranose as described by us pre-
viously.18 It was coupled under Vorbru¨ggen conditions
with silylated 2-amino-6-chloropurine to give 11 in
79% yield. Classical procedures allowed a straightfor-
ward conversion of 11 to 13. Triphenylphosphine reduc-
tion of the azido moiety yielded the corresponding
amine 7.
Based on the results of Cristalli et al.19 we have chosen
phenylethynyl as the most promising C2-substituent.
Reaction conditions used to perform a Sonogashira
coupling20 of 13 with phenylacetylene yielded the 3 0-(4-
phenyl-1,2,3-triazol-1-yl) derivative (15) of the 2-alkyny-
lated compound (Scheme 1). This result was due to aScheme 1. Reagents and conditions: (a) i—HMDS, (NH4)2SO4, reﬂux, 20
CH2I2 in THF, reﬂux; (c) CH3NH3Cl, Et3N, EtOH, reﬂux; (d) Ph3P, H2O,Cu+-catalysed Huisgen dipolar cycloaddition21 of the
3 0-azide with phenylacetylene. Consequently, another
strategy was used to gain access to compound 14
(Scheme 2), starting from 6-chloro-2-iodo-(9-tetrahy-
dropyran-2-yl)purine (16), obtained from the 2-unsub-
stituted analogue via a lithiation-mediated stannyl
transfer process followed by 2-tributylstannyl-iodine ex-
change.22 Sonogashira coupling of 17, followed by
deprotection, provided 19. Unfortunately, classical
Vorbru¨ggen coupling,23 as described for the synthesis
of 11, did not give satisfying results. By using N,O-
bis(trimethylsilyl)acetamide (BSA) as silylating agent,24
9-(2-acetyl-3-azido-3-deoxy-5-methylcarbamoyl-b-D-ribo-
furanosyl)-N6-methyl-2-phenylethynyladenine (20) was
obtained in poor yield.
During the course of this work it became clear that the
3 0-amino-analogues generally exhibit much better A3AR
aﬃnities than their 3 0-azide precursors. Consequently,
we focussed only on the 3 0-amino derivatives for furtherh, ii—2-amino-6-chloropurine, TMSOTf; (b) isoamyl nitrite, I2, CuI,
THF, 2 days; (e) phenylacetylene, (PPh3)2PdCl2, CuI, Et3N, DMF.
Scheme 3. Reagents and conditions: (a) 2-amino-6-chloropurine, BSA, TMSOTf, CH3CN, reﬂux; (b) isoamylnitrite, I2, CuI, CH2I2 in THF, reﬂux;
(c) i—CH3NH3Cl, Et3N, EtOH, reﬂux, ii—7 N NH3 in MeOH; (d) Na in MeOH; (e) Ph3P, H2O, THF, 2 days; (f) alkyne, (PPh3)2PdCl2, CuI, Et3N,
DMF.
Scheme 2. Reagents and conditions: (a) CH3NH3Cl, DMAP, EtOH, reﬂux; (b) phenylacetylene (PPh3)2PdCl2, CuI, Et3N, DMF; (c) TFA, CH2Cl2;
(d) 10, BSA, TMSOTf, CH3CN reﬂux; (e) 7 N NH3 in MeOH; (f) Ph3P, H2O, THF, 2 days.
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azide to a 3 0-amine before the Sonogashira coupling,
avoiding the unwanted cycloaddition.
9-(3-Amino-3-deoxy-b-D-ribofuranosyl)-N6-methyl-2-iodo-
purine (1) served as a suitable synthon for the synthesis
of the 2-alkynylated 3 0-amino-adenosines 3–5 (Scheme
3). It was obtained by coupling of sugar 21 with 2-ami-
no-6-chloropurine. Elaboration of the base moiety to
yield 25 was essentially accomplished as for 13. Stau-
dinger reduction allowed the unmasking of the amine
group. Finally, Sonogashira coupling on amine 1 pro-
vided the alkynylated analogues 3–5 in 80–82% yield.
To continue the exploration of the 2-position, we
synthesized the 2-I and the 2-NH2 derivatives of the
5 0-OH and the 2-H and the 2-I derivatives of the
5 0-methylcarbamoyl 3 0-amino-N6-aminomethyl adeno-
sine analogues (Scheme 4).3 0-Amine 6 (Fig. 1) was prepared by catalytic hydroge-
nation of the 3 0-azide precursor which has been
described.18
2.2. Biological evaluation
For the adenosine derivatives prepared in this study
(1–9, 13, 14, 15, 25, 27 and 29) we measured both
the binding aﬃnities at the hA1, hA2A and hA3AR
and their degrees of activation of the A3AR subtype.
The results are reported in Table 1. The ability of each
of these adenosine derivatives to compete for radioli-
gand binding at each of these hARs was evaluated at
a ﬁxed concentration of 10 lM, and full competition
curves were determined at the A3AR. Six diﬀerent 2-
substituents were included: H, I, NH2, Ph-C„C,
pMePh-C„C and nBu-C„C. The choice of the methyl
group as a small N6 substituent was based on the
results of Cristalli et al., who demonstrated that it
Table 1. Binding aﬃnities of adenine derivatives at human A1, A2A and A3ARs expressed in CHO cells
a
N
NN
N
N
O
OHR3
R2
R1
H Me
Compound R1 R2 R3 % Inhibition (hA3AR) Ki (nM) % Activation
d (hA3AR)
(hA1AR) (%) (hA2AAR) (%)
1 I CH2OH NH2 39 12 879 ± 346 67 ± 6
2 NH2 CH2OH NH2 16 4 654 ± 42 57 ± 2
3 Ph-C„C CH2OH NH2 50 14 126 ± 4 36 ± 6
4 pMePh-C„C CH2OH NH2 33 0 145 ± 35 23 ± 3
5 nBu-C„C CH2OH NH2 4 3 389 ± 112 66 ± 11
6 H CONHMe NH2 18 12 32.3 ± 3.9 72 ± 10
7 I CONHMe NH2 16 24 71.4 ± 12.8 18 ± 10
8 NH2 CONHMe NH2 14 10 536 ± 247 92 ± 3
9 Ph-C„C CONHMe NH2 9 9 15.6 ± 3.6 67 ± 11
13 I CONHMe N3 16 0 2530
b 8 ± 5
14 Ph-C„C CONHMe N3 31 16 78.9 ± 12.4 11 ± 8
15 Ph-C„C CONHMe 4-Ph-1,2,3-triazol-1-yl 14 2 1820 ± 770 0
25 I CH2OH N3 85
b,c 27% 6540 ± 320 3 ± 2
27 NH2 CH2OH N3 49 16 28,800
b 0
2918 H CONHMe N3 12 10 1140 ± 300 38 ± 4
a All A3AR experiments were performed using adherent CHO cells stably transfected with cDNA encoding one of the human adenosine receptors.
Binding at human A1, A2A and A3ARs in this study was carried out as described in methods using [
3H]PIA, [3H]CGS 21680 or [125I]AB-MECA as
radioligand. Values from the present study are expressed as Ki values (means ± SEM, n = 3, unless noted) or as percent displacement of radioligand
at 10 lM.
b n = 1.
cKi (A1 AR) = 1850 nM.
d% Inhibition at 100 lM of forskolin-stimulated cAMP production at 10 lM, in CHO cells expressing the hA3AR, as a percentage of the response of
the full angonist CI-IB-MECA (n = 3).
Scheme 4. Reagents and conditions: (a) i—CH3NH3Cl, Et3N, EtOH, reﬂux, ii—7 N NH3 in MeOH; (b) Na in MeOH; (c) Ph3P, H2O, THF, 2 days.
1406 L. Cosyn et al. / Bioorg. Med. Chem. 14 (2006) 1403–1412increased the aﬃnity for the human A3AR and signif-
icantly enhanced the A3AR selectivity.
19
Results from the competition experiments showed that
the A3AR aﬃnities of the 3
0-amines were much higherthan those of the 3 0-azides. For all derivatives studied,
the 5 0-methylcarbamoyl modiﬁcation, in general, en-
hanced the aﬃnity at the A3AR in comparison to 5
0-
CH2OH. Except for 25, all evaluated compounds showed
a very high selectivity for theA3ARcompared to the other
L. Cosyn et al. / Bioorg. Med. Chem. 14 (2006) 1403–1412 1407ARs. The most potent compound (9) displayed aKi value
of 16 nM at the A3AR. The C-2 substituent of this com-
pound, a phenylethynyl moiety, was previously shown
to enhance A3AR aﬃnity and selectivity,
19 and proved
to have a superior contribution to A3AR aﬃnity than a
p-methyl-phenylethynyl (4) or a 1-hexynyl (5) moiety.
Furthermore, the 2-phenylethynylmodiﬁcation appeared
to overcome the reduction of aﬃnity caused by the
3 0-azide (cf.Ki = 78.9 nM for 14 vs 1140 nM for 29). Con-
sequently, this C-2 substituent was selected to be com-
bined with a 3 0-amino and a 5 0-methylcarbamoyl
modiﬁcation.
Previous studies showed that 3 0-amino derivatives exhibit
a decreased aﬃnity at the A3AR compared to their 3
0-hy-
droxy analogues. The aﬃnity reduction associated with
this 3 0 modiﬁcation could be overcome by elaborating
theN6-substituents, for examplewith a substituted benzyl
group.17 The high aﬃnity of compound 9 (Ki = 15.6 nM)
demonstrated that a 2-phenylethynylmodiﬁcation in con-
cert with a small N6-substituent was likewise capable of
overcoming this reduction in aﬃnity. Note that in our
experiments the aﬃnity of derivative 6 for the A3AR
(Ki = 32.3 nM) was 4-fold higher than that reported by
DeNinno et al.15 The 2-I analogue 7 also showed appre-
ciable A3AR aﬃnity (Ki = 71.4 nM). Conversely, the 2-
NH2 analogue 8 exhibited weak A3AR aﬃnity
(Ki = 536 nM).
The results of the cyclic cAMP-assay (Table 1) indicated
that all 3 0-azides were A3AR antagonists, except for
compound 29 which showed partial agonist activity.
Also the 3 0-(4-phenyl-1,2,3-triazol-1-yl) derivative 15 ap-
peared to be an A3AR antagonist. All other compounds
were partial agonists, except for compound 8, which
manifested full agonist activity.3. Conclusions
The 2,3 0,5 0-trisubstituted and 2,3 0-disubstituted N6-
methyl adenosine derivatives described in the present
study were synthesized in good overall yields. All the
compounds had A3AR aﬃnities in the low micromolar
or nanomolar range and showed very high A3AR selec-
tivity. The 3 0-azides appeared to be A3AR antagonists
with a moderate A3AR aﬃnity. The 3
0-amino modiﬁca-
tion signiﬁcantly improved the A3AR aﬃnity and result-
ed in partial A3AR agonists. For both the 3
0-azido and
the 3 0-amino derivatives, the 5 0-methylcarbamoyl modi-
ﬁcation improved the overall aﬃnity. Curiously, the
presence of a 5 0-uronamide did not restore full A3AR
eﬃcacy in 2-position derivatives, as was demonstrated
in the case of N6-substituents that reduced eﬃcacy.26
The 2-phenylethynyl derivative 9 demonstrated high
A3AR receptor aﬃnity with a Ki value of 15.6 nM and
>1000-fold selectivity. Previous studies revealed that
3 0-amines exhibit a decreased aﬃnity compared to their
3 0-hydroxy analogues. This study demonstrated that
introduction of a 2-phenylethynyl substituent in concert
with the N6-methyl group is capable of overcoming this
aﬃnity drop.4. Experimental
4.1. Chemicals and solvents
All reagents were from standard commercial sources
and of analytic grade.
4.2. Chromatography
Precoated Merck silica gel F254 plates were used for
TLC and spots were examined under UV light at
254 nm and further visualized by sulfuric acid-anisalde-
hyde spray. Column chromatography was performed on
Uetikon silica (0.2–0.06 mm).
4.3. Instruments and analyses
NMR spectra were obtained with a Varian Mercury
300 MHz spectrometer. Chemical shifts are given in
ppm (d) relative to the residual solvent signal, in the
case of DMSO-d6 2.54 ppm for
1H and in the case of
CDCl3 7.26 ppm for
1H. All signals assigned to amino,
amide hydrogen and hydroxyl groups were exchange-
able with D2O. Exact mass measurements were per-
formed on a quadrupole/orthogonal-acceleration time-
of-ﬂight (Q/oaTOF) tandem mass spectrometer (qToF
2, Micromass, Manchester, UK) equipped with a stan-
dard electrospray ionization (ESI) interface. Samples
were infused in a 2-propanol/water (1:1) mixture at
3 lL/min.
4.4. 9-(3-Amino-3-deoxy-b-D-ribofuranosyl)-2-iodo-N6-
methyladenine (1)
This compound was synthesized from 30 mg
(0.069 mmol) of 25 by the procedure described for
the synthesis of 7; yield: 26 mg (92%). 1H NMR
(300 MHz, DMSO-d6): d 1.66 (br s, 2H, NH2), 2.87
(d, 3H, J = 4 Hz, N6-CH3), 3.41 (app t, 1H,
J = 6.0 Hz, H3 0), 3.54–3.71 (m, 3H, H4 0 and H5 0A
and H5 0B), 4.10 (br s, 1H, 2 0-OH), 4.19 (dd, 1H,
J = 2.6 and 4.4 Hz, H2 0), 4.98 (br s, 1H, 5 0-OH), 5.82
(d, 1H, J = 2.6 Hz, H1 0), 8.11 (d, 1H, J = 4 Hz, N6H),
8.30 (s, 1H, H8); Exact Mass (ESI-MS, i-PrOH/H2O):
Calcd for C11H16N6O3I[M+H]
+: 407.0330. Found:
407.0332.
4.5. 9-(3-Amino-3-deoxy-b-D-ribofuranosyl)-2-amino-N6-
methyladenine (2)
This compound was synthesized from 27 (35 mg,
0.11 mmol) by the procedure described for the syn-
thesis of 7; yield: 30 mg (93%). 1H NMR
(300 MHz, DMSO-d6): d 1.70 (br s, 2H, 3 0-NH2),
2.86 (s, 3H, N6-CH3), 3.34 (app t, 1H, J = 6.0 Hz,
H3 0), 3.52–3.70 (m, 3H, H4 0 and H5 0A and
H5 0B), 4.16 (br s, 2H, 2 0-OH and H2 0), 5.16 (br
s, 1H, 5 0-OH), 5.74 (d, 1H, J = 2.8 Hz, H1 0), 5.83
(s, 2H, 2-NH2), 7.24 (br s, 1H, N
6H), 7.91 (s,
1H, H8); Exact Mass (ESI-MS, i-PrOH/H2O): Calcd
for C12H18N7O3 [M+H]
+: 296.1471. Found:
296.1470.
1408 L. Cosyn et al. / Bioorg. Med. Chem. 14 (2006) 1403–14124.6. General procedure for the synthesis of alkynes 3, 4 and 5
from 1
Compound 1 (50 mg, 0.12 mmol) was dissolved in Et3N
(1.5 mL) and DMF (1 mL). After purging the solution
with N2, (PPh3)2PdCl2 (8.6 mg, 0.012 mmol) and CuI
(2.3 mg, 0.012 mmol) were added. The appropriate al-
kyne (2 equiv) was subsequently added dropwise and
the mixture was stirred at room temperature for 3 h.
The solvents were removed under reduced pressure,
the residue was taken up in ethyl acetate and the solu-
tion was ﬁltered over a Celite pad. The residue remain-
ing after solvent evaporation was puriﬁed on silica gel
column (CH2Cl2/MeOH, 90:10).
4.7. 9-(3-Amino-3-deoxy-b-D-ribofuranosyl)-N6-methyl-2-
phenylethynyladenine (3)
The reaction of 1 (50 mg, 0.12 mmol) with phenylacety-
lene (27 lL, 0.24 mmol) gave compound 3 in 81% yield.
1H NMR (300 MHz, DMSO-d6) d 2.07 (br s, 2H, 3 0-
NH2), 2.94 (s, 3H, N
6-CH3), 3.44 (app t, 1H, J = 5.3 Hz,
H3 0), 3.56–3.75 (m, 3H, H4 0 and H5 0A and H5 0B), 4.09
(br s, 1H, 2 0-OH), 4.24 (dd, 1H, J = 2.6 and 4.4 Hz,
H2 0), 5.11 (br s, 1H, 5 0-OH), 5.94 (d, 1H, J = 2.3 Hz,
H1 0), 7.46 (m, 3H, Ph), 7.61 (m, 2H, Ph), 7.95 (br s, 1H,
N6H), 8.47 (s, 1H, H8); Exact Mass (ESI-MS, i-PrOH/
H2O): Calcd for C19H21N6O3[M+H]
+: 381.1675. Found:
381.1675.
4.8. 9-(3-Amino-3-deoxy-b-D-ribofuranosyl)-N6-methyl-2-
(4-methyl-phenyl)ethynyladenine (4)
The reaction of 1 (50 mg, 0.12 mmol) with 4-methyl-
phenylacetylene (31 lL, 0.24 mmol) gave compound 4
in 82% yield. 1H NMR (300 MHz, DMSO-d6) d 2.33
(s, 3H, CH3Ph), 2.94 (s, 3H, N
6-CH3), 3.50–3.79 (m,
4H, H3 0, H4 0, H5 0A and H5 0B), 4.31 (dd, 1H, J = 2.4
and 4.5 Hz, H2 0), 5.15 (br s, 1H, 5 0-OH), 5.74 (s, 1H,
2 0-OH), 5.96 (d, 1H, J = 2.4 Hz, H1 0), 7.25 (m, 2H,
Ph), 7.50 (m, 2H, Ph), 7.95 (br s, 1H, N6H), 8.46 (s,
1H, H8); Exact Mass (ESI-MS, i-PrOH/H2O): Calcd
for C20H23N6O3[M+H]
+: 395.1831. Found: 395.1823.
4.9. 9-(3-Amino-3-deoxy-b-D-ribofuranosyl)-N6-methyl-2-
(1-hexyn-1-yl)adenine (5)
The reaction of 1 (50mg, 0.12 mmol)with 1-hexyn (28 lL,
0.24 mmol) gave compound 5 in 80% yield. 1H NMR
(300 MHz, DMSO-d6) d 0.90 (t, 3H, J = 7.03 Hz,
CH2CH3), 1.37–1.54 (m, 4H, CH2CH2CH3), 2.41 (t, 2H,
J = 7.04 Hz, C„CCH2), 2.88 (s, 3H, N
6-CH3), 3.48–
3.73 (m, 4H, H3 0, H4 0, H5 0A and H5 0B), 4.10–4.23 (m,
2H, H2 0 and 2 0-OH), 5.10 (br s, 1H, 5 0-OH), 5.90 (d,
1H, J = 2.5 Hz, H1 0), 7.83 (br s, 1H, N6H), 8.41 (s, 1H,
H8); Exact Mass (ESI-MS, i-PrOH/H2O): Calcd for
C17H25N6O3[M+H]
+: 361.1988. Found: 361.1982.
4.10. 9-(3-Amino-3-deoxy-5-methylcarbamoyl-b-D-
ribofuranosyl)-N6-methyl-2-iodoadenine (7)
Compound 13 (50 mg, 0.11 mmol) and PPh3 (57 mg,
0.21 mmol) were dissolved in THF (2 mL). After stirringfor 10 min, H2O was added (270 lL, 15 lmol) and the
reaction mixture was stirred for 2 days. The residue ob-
tained after solvent evaporation was puriﬁed by column
chromatography (CH2Cl2/MeOH, 95:5) to yield 82% of
compound 7. 1H NMR (300 MHz, DMSO-d6): d 1.79 (s,
2H, 3 0-NH2), 2.69 (d, 3H, J = 4.7 Hz, CH3NHCO), 2.88
(d, 3H, J = 4.1 Hz, N6-CH3), 3.54 (t, 1H, J = 11.1 Hz,
H3 0), 4.10 (d, 1H, J = 6.2 Hz, H4 0), 4.30 (app t, 1H,
J = 8.8 Hz, H2 0), 5.91 (br s, 1H, 2 0-OH), 5.93 (d, 1H,
J = 3.81 Hz, H1 0), 8.03 (d, 1H, J = 4,7 Hz, NHCO),
8.13 (d, 1H, J = 4.1 Hz, N6H), 8.48 (s, 1H, H8); Exact
Mass (ESI-MS, i-PrOH/H2O): Calcd for C12H17ClI-
N7O3[M+H]
+: 434.0439. Found: 434.0445.
4.11. 9-(3-Amino-3-deoxy-5-methylcarbamoyl-b-D-
ribofuranosyl)-2-amino-N6-methylpurine (8)
Compound 28 (40 mg, 0.12 mmol) and PPh3 (66 mg,
0.25 mmol) were dissolved in THF (2 mL). After stirring
for 10 min, H2O was added (310 lL, 17 mmol) and the
mixture was stirred for 2 days. The residue obtained after
solvent evaporation was puriﬁed by column chromatog-
raphy (CH2Cl2/MeOH, 80:20) to give compound 8 in
80% yield. 1H NMR (300 MHz, DMSO-d6): d 2.95 (br s,
2H, 3 0-NH2), 2.66 (d, 3H, J = 4.7 Hz, CH3NHCO), 2.86
(s, 3H, N6-CH3), 3.54 (app t, 1H, J = 5.4 Hz, H3
0), 4.05
(d, 1H, J = 5.6 Hz, H4 0), 4.37 (app t, 1H, J = 4.7 Hz,
H2 0), 5.82 (d, 1H, J = 4.1 Hz, H1 0), 5.88 (s, 2H, 2-NH2),
7.31 (s, 1H, N6H), 8.04 (s, 1H, H8), 8.27 (d, 1H,
J = 4.4 Hz, NHCO); Exact Mass (ESI-MS, i-PrOH/
H2O): Calcd for C12H19N8O3[M+H]
+: 323.1580. Found:
323.1579.
4.12. 9-(3-Amino-3-deoxy-5-methylcarbamoyl-b-D-
ribofuranosyl)-N6-methyl-2-phenylethynyladenine (9)
This compound was synthesized by the procedure de-
scribed for the synthesis of 7 from 20 mg (0.046 mmol)
of 14 in 96% yield (18 mg). 1H NMR (300 MHz,
DMSO-d6): d 1.78 (s, 2H, 3 0-NH2), 2.71 (d, 3H,
J = 4.4 Hz, CH3NHCO), 2.94 (s, 3H, N
6-CH3), 4.33 (dd,
1H, J = 5.0 and 5.3 Hz, H3 0), 4.13 (d, 1H, J = 5.3 Hz,
H4 0), 4.36 (br s, 1H, H2 0), 5.94 (s, 1H, 2 0-OH), 6.02 (d,
1H, J = 4.40, H1 0), 7.46 (m, 3H, Ph), 7.61 (m, 2H, Ph),
8.04 (d, 1H, J = 4.4 Hz, N6H), 8.41 (d, 1H, J = 4.7 Hz,
NHCO), 8.62 (s, 1H, H8); Exact Mass (ESI-MS, i-
PrOH/H2O): Calcd for C20H22N7O3[M+H]
+: 408.1784.
Found: 408.1787.
4.13. 9-(2-O-Acetyl-3-azido-3-deoxy-5-methylcarbamoyl-
b-D-ribofuranosyl)-2-amino-6-chloropurine (11)4.13.1. Silylation of the base. 2-Amino-6-chloropurine
(462 mg, 2.7 mmol) was treated with 1,1,1,3,3,3-hexam-
ethyldisilazane (HMDS, 40 mL) and (NH4)2SO4
(0.27 mmol, 36 mg) and reﬂuxed for 20 h. The silylated
compound was concentrated and used without further
puriﬁcation.
4.13.2. Vorbru¨ggen coupling. 3-Azido-3-deoxy-1,2-di-O-
acetyl-a-D-ribofuronamide (10, 600 mg, 2.09 mmol) in
dry 1,2-dichloroethane (25 mL) was added to the silylated
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tion was gently reﬂuxed, and after 5 min TMSOTf
(417lL, 2.3 mmol) was added dropwise. After 4 h, the
mixture was cooled to room temperature, quenched with
a cold saturated NaHCO3 solution (80 mL) and extract-
ed with CH2Cl2 (40 mL). The organic layer was dried
with MgSO4, ﬁltered and evaporated to dryness. The
residue was puriﬁed by column chromatography
(CH2Cl2/MeOH, 98:2) to give 650 mg (79%) of com-
pound 11. 1H NMR (300 MHz, CDCl3): d 2.15 (s, 3H,
CH3CO), 2.90 (d, 3H, J = 5.0 Hz, CH3N), 4.53 (d, 1H,
J = 3.2 Hz, H4 0), 4.90 (dd, 1H, J = 3.5 and 5.0 Hz,
H3 0), 5.14 (s, 2H, NH2), 5.94 (t, 1H, J = 5.3 Hz, H2 0),
5.97 (d, 1H, J = 6.2 Hz, H1 0), 7.09 (br s, 1H, NHCO),
7.82 (s, 1H, H8); Exact Mass (ESI-MS, i-PrOH/H2O):
Calcd for C13H15ClN9O4[M+H]
+: 396.0935. Found:
396.0932.
4.14. 9-(2-O-Acetyl-3-azido-3-deoxy-5-methylcarbamoyl-
b-D-ribofuranosyl)-6-chloro-2-iodopurine (12)
Isoamylnitrite (681 lL, 4.98 mmol) was added to a
mixture of 11 (650 mg, 1.65 mmol), I2 (418 mg,
1.65 mmol), CH2I2 (1.37 mL, 16.5 mmol) and CuI
(330 mg, 1.72 mmol) in 15 mL THF. The mixture
was reﬂuxed for 45 min and then cooled to room tem-
perature. Insoluble materials were removed by ﬁltra-
tion, and the ﬁltrate was concentrated to dryness.
The residue was puriﬁed by means of a silica gel col-
umn, which was washed with CH2Cl2 until the iodine
colour disappeared and then eluted with CH2Cl2/
MeOH, 98:2. Compound 12 was obtained in 79%
yield. 1H NMR (300 MHz, CDCl3): d 2.13 (s, 3H,
CH3CO), 3.06 (d, 3H, J = 4.98 Hz, CH3N), 4.56 (d,
1H, J = 2.9 Hz, H4 0), 4.80 (dd, 1H, J = 2.9 and
5.6 Hz, H3 0), 5.75 (dd, 1H, J = 5.9 and 7.0 Hz, H2 0),
6.06 (d, 1H, J = 7.3 Hz, H1 0), 7.09 (br s, 1H, NHCO),
8.11 (s, 1H, H8); Exact Mass (ESI-MS, i-PrOH/H2O):
Calcd for C13H13ClIN8O4[M+H]
+: 506.9794. Found:
506.9822.
4.15. 9-(3-Azido-3-deoxy-5-methylcarbamoyl-b-D-
ribofuranosyl)-N6-methyl-2-iodoadenine (13)
Compound 12 (460 mg, 0.91 mmol) was dissolved in
EtOH (10 mL). Methylammonium chloride (92 mg,
1.36 mmol) and Et3N (158 lL, 1.13 mmol) were added,
and the solution was reﬂuxed overnight. The mixture
was concentrated to dryness, dissolved in 7 N NH3 in
methanol and stirred at room temperature for 2 h to
deprotect the 2 0-hydroxyl group. The volatiles were re-
moved under reduced pressure, and the residue was
puriﬁed by silica gel column (CH2Cl2/MeOH, 98:2).
The product, 13, was realized, in 77% yield. 1H NMR
(300 MHz, DMSO-d6): d 2.71 (d, 3H, J = 4.7 Hz,
CH3NHCO), 2.89 (d, 3H, J = 4.4 Hz, N
6-CH3), 4.33
(d, 1H, J = 3.5 Hz, H4 0), 4.47 (dd, 1H, J = 3.5 and
5.0 Hz, H3 0), 4.92 (dd, 1H, J = 5.6 and 11.4 Hz, H2 0),
5.89 (d, 1H, J = 6.5 Hz, H1 0), 6.33 (d, 1H, J = 5.6 Hz,
2 0-OH), 8.10 (d, 1H, J = 4,7 Hz, NHCO), 8.17 (d, 1H,
J = 4.7 Hz, N6H), 8.36 (s, 1H, H8); Exact Mass (ESI-
MS, i-PrOH/H2O): Calcd for C12H15IN9O3[M+H]
+:
460.0344. Found: 460.0350.4.16. 9-(3-Azido-3-deoxy-5-methylcarbamoyl-b-D-
ribofuranosyl)-N6-methyl-2-phenylethynyladenine (14)
A solution of compound 20 (30 mg, 0.06 mmol) and
10 mL of 7 NNH3 in methanol was kept at room temper-
ature for 2 h to allow deprotection of the 2 0-hydroxyl
group. Themixturewas concentrated to dryness andpuri-
ﬁed on a silica gel column (CH2Cl2/MeOH, 97:3). A 91%
yield of compound 14was obtained. 1HNMR (300 MHz,
DMSO-d6): d 2.73 (d, 3H, J = 3.5 Hz, CH3NHCO), 2.96
(s, 3H, N6-CH3), 4.33 (d, 1H, J = 2.6 Hz, H4
0), 4.51 (dd,
1H, J = 3.0 and 5.27 Hz, H3 0), 4.96 (app t, 1H,
J = 5.3 Hz, H2 0), 5.98 (d, 1H, J = 6.7 Hz, H1 0), 7.46 (m,
3H, Ph), 7.64 (m, 2H, Ph), 8.12 (s, 1H, N6H), 8.51 (s,
1H, H8), 8.53 (d, 1H, J = 4.4 Hz, NHCO); Exact Mass
(ESI-MS, i-PrOH/H2O): Calcd for C20H20N9O3[M+H]
+:
434.1688. Found: 434.1686.
4.17. Attempted synthesis of compound 14
Attempted conversion of 13 to 14 using the procedure as
described for 3, 4 and 5 failed to give 14, but resulted in
the formation of triazole 15 as the sole reaction product.
1H NMR (300 MHz, DMSO-d6): d 2.78 (d, 3H,
J = 4.6 Hz, N6-CH3), 3.0 (br s, 3H, CH3NHCO), 5.15
(app q, 1H, J = 6.3 Hz, H2 0), 5.17 (d, 1H, J = 3.4 Hz,
H4 0), 5.61 (dd, 1H, J = 3.6 and 6.3 Hz, H3 0), 6.26 (d,
1H, J = 5.4 Hz, 2 0OH), 6.27 (d, 1H, J = 6.3 Hz, H1 0),
7.36 (t, 1H, J = 7.3 Hz, 400-Ph), 7.46–7.51 (m, 2H, 400-
Ph and 3H, C„CPh), 7.65 (br d, 2H, J = 6.8 Hz,
C„CPh), 7.90 (d, 2H, J = 7.6 Hz, 400-Ph), 8.59 (s, 1H,
H8), 8.71 (m, 2H, H500 and NHCO); Exact Mass (ESI-
MS, i-PrOH/H2O): Calcd for C28H25N9O3[M+H]
+:
536.2158. Found: 536.2166.
4.18. 2-Iodo-N6-methyl-(9-tetrahydropyran-2-yl)adenine
(17)
Methylammonium chloride (28 mg, 0.41 mmol) and
DMAP (67 mg, 0.54 mmol) were added to 100 mg
(0.27 mmol) of compound 16 in EtOH (6 mL), and the
solution was reﬂuxed overnight. The mixture was con-
centrated to dryness and the residue was puriﬁed on a
silica gel column (pentane/ethyl acetate, 50:50). The title
compound was obtained in 81% yield. 1H NMR
(300 MHz, DMSO-d6): d 1.52 (m, 6H, H2A 0 and
H2B 0, H3A 0 and H3B 0, H4A 0 and H4B 0), 2.87 (s, 3H,
NH CH3), 3.68 (t, 1H, J = 11.4 Hz, H5
0A), 3.96 (app
d, 1H, J = 11.4 Hz, H5 0B), 5.43 (dd, 1H, J = 2.3 and
10.9 Hz, H1 0), 7.26 (br s, 1H, NHCH3), 7.87 (s, 1H,
H8); Exact Mass (ESI-MS, i-PrOH/H2O): Calcd for
C11H15N5O3I[M+H]
+: 360.0323. Found: 360.0333.
4.19.N6-Methyl-2-phenylethynyl-tetrahydropyranyladenine
(18)
Compound 17 (200 mg, 0.557 mmol) was dissolved in a
mixture of Et3N (3 mL) and DMF (1 mL) and the solu-
tion was purged with N2. (PPh3)2PdCl2 (39 mg,
0.056 mmol) and CuI (10.6 mg, 0.056 mmol) were added.
Phenyl acetylene (112 lL, 1.11 mmol) was subsequently
added dropwise, and the mixture was stirred at room
temperature for 3 h. The solvents were removed under
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and the resulting solutionwas ﬁltered over a pad ofCelite.
After solvent evaporation, the residue was puriﬁed on a
silica gel column (pentane/ethyl acetate, 50:50) to give
compound 18 in 91% yield. 1HNMR (300 MHz, CDCl3):
d 1.18–2.25 (m, 6H, H2A 0 and H2B 0, H3A 0 and H3B 0,
H4A 0 and H4B 0), 3.21 (s, 3H, NH CH3), 3.72 (app t,
1H, J = 11.4 Hz, H5 0A), 3.96 (app d, 1H, J = 10.3 Hz,
H5 0B), 5.79 (d, 1H, J = 9.1 Hz, H1 0), 7.20 (s, 1H, H8),
7.30 (d, 3H, J = 5.3 Hz, H-Ph), 7.61 (m, 2H,H-Ph); Exact
Mass (ESI-MS, i-PrOH/H2O): Calcd for C19H20N5
O[M+H]+: 334.1667. Found: 334.1671.
4.20. N6-Methyl-2-phenylethynylpurine (19)
To a solution of 18 (170 mg, 0.510 mmol) in 10 mL of
CH2Cl2 was added slowly a solution of 0.78 mL TFA
(10.2 mmol) and 0.78 mL CH2Cl2. After stirring at room
temperature for 1 h, the solvent was evaporated, and the
residue was taken up in ethyl acetate, and the solution
was washed with 7% NaHCO3. After silica gel chroma-
tography (CH2Cl2/MeOH, 97:3), pure 19 was obtained
in a 72% yield. 1H NMR (300 MHz, DMSO): d 2.97
(s, 3H, NH CH3), 7.30 (m, 3H, H-Ph), 7.61 (m, 2H,
H-Ph), 7.88 (br s, 1H, NHCH3), 8.24 (s, 1H, H8); Exact
Mass (ESI-MS, i-PrOH/H2O): Calcd for
C14H12N5[M+H]
+: 250.1092. Found: 250.1073.
4.21. 9-(2-Acetyl-3-azido-3-deoxy-5-methylcarbamoyl-b-
D-ribofuranosyl)-N6-methyl-2-phenylethynyladenine (20)
Toamixture of 19 (150 mg, 0.602 mmol) andmethyl 3-az-
ido-3-deoxy-1,2-di-O-acetyl-a-D-ribofuronamide (10)
(207 mg, 0.722 mmol) in 3 mL CH3CN were successively
added 223 lL (0.903 mmol) of N,O-bis(trimethylsilyl)-
acetamide (BSA) and 131 lL (0.722 mmol) TMSOTf.
The suspension was reﬂuxed for 10 h. After being cooled
to room temperature, the reaction was quenched with 7%
NaHCO3 and extracted with CH2Cl2. The organic layer
waswashedwithbrine, ﬁltered through a short padofCel-
ite and evaporated to dryness. The crude material was
puriﬁed by column chromatography (CH2Cl2/MeOH,
99:1), and compound 20 was obtained in 24.4% yield.
1H NMR (300 MHz, DMSO-d6): d 2.12 (s, 3H, CH3CO),
3.02 (d, 3H, J = 4.69 Hz, CH3NHCO), 3.25 (s, 3H, N
6-
CH3), 4.58 (d, 1H, J = 2.6 Hz, H4
0), 4.78 (dd, 1H,
J = 2.1 and 5.3 Hz, H3 0), 5.78 (dd, 1H, J = 7.3 and
12.9 Hz, H2 0), 5.92 (s, 1H, N6H) 6.02 (d, 1H, J = 7.6 Hz,
H1 0), 7.40 (app d, 3H, J = 7.0 Hz H-Ph), 7.63 (app d,
2H, J = 9.1 Hz, H-Ph), 7.81 (s, 1H, H8), 8.83 (s, 1H,
NHCO); Exact Mass (ESI-MS, i-PrOH/H2O): Calcd for
C22H22N9O4[M+H]
+: 476.1794. Found: 476.1800.
4.22. 9-(2-Acetyl-3-azido-3-deoxy-5-O-toluoyl-b-D-
ribofuranosyl)-2-amino-6-chloropurine (22)
To a mixture of 2-amino-6-chloropurine (90 mg, 0.53
mmol) and 3-azido-3-deoxy-1,2-di-O-acetyl-5-O-toluo-
yl-a-D-ribofuranose (21) (240 mg, 0.64 mmol) in 3 mL
CH3CN were successively added 196 lL (0.79 mmol)
BSA and 115 lL (0.64 mmol) TMSOTf. The suspension
was heated at 80 C for 3 h. After being cooled to room
temperature, the reaction was quenched with 7% NaH-CO3 and extracted with CH2Cl2. The organic layer was
washed with brine, ﬁltered through a short Celite pad
and evaporated to dryness. The residue was puriﬁed by
column chromatography (CH2Cl2/MeOH, 99:1) to yield
200 mg (65%) of compound 22. 1H NMR (300 MHz,
CDCl3): d 2.19 (s, 3H, CH3CO), 2.41(s, 3H, CH3-Ph),
4.40 (m, 1H, H4 0), 4.52–4.58 (m, 1H, H5 0A 0), 4.76–4.82
(m, 2H, H3 0 and H5 0B), 5.13 (br s, 2H, NH2), 5.94
(d, 1H, J = 3.8 Hz, H1 0), 5.80 (dd, 1H, J = 3.8 and
5.6 Hz, H2 0), 7.23 (d, 2H, J = 7.63 Hz, Ph), 7.79 (s,
1H, H8), 7.86 (d, 2H, J = 8.2 Hz, Ph); Exact Mass (ESI-
MS, i-PrOH/H2O): Calcd for C20H19N8O5Cl[M+H]
+:
487.1245. Found: 487.1246.
4.23. 9-(2-Acetyl-3-azido-3-deoxy-5-O-toluoyl-b-D-
ribofuranosyl)-6-chloro-2-iodopurine (23)
This compound was prepared by the procedure described
for the synthesis of 12 from 22 (200 mg, 0.41 mmol); yield:
200 mg (81%). 1HNMR (300 MHz, DMSO-d6): d 2.15 (s,
3H, CH3CO), 2.35 (s, 3H, CH3-Ph), 4.37 (dd, 1H, J = 4.1
and 7.6 Hz, H4 0), 4.52 (dd, 1H, J = 4.4 and 12.3 Hz,
H5 0A 0), 4.65 (dd, 1H, J = 3.2 and 12.3 Hz, H5 0B), 4.96
(dd, 1H, J = 5.8 and 7.6 Hz, H3 0), 6.03 (dd, 1H, J = 2.6
and 5.28 Hz, H2 0), 6.29 (d, 1H, J = 2.9 Hz, H1 0), 7.24
(d, 2H, J = 7.9 Hz, Ph), 7.68 (d, 2H, J = 8.2 Hz, Ph),
8.74 (s, 1H, H8); Exact Mass (ESI-MS, i-PrOH/H2O):
Calcd forC20H17N7O5ClINa[M+Na]
+: 619.9924. Found:
619.9920.
4.24. 9-(3-Azido-3-deoxy-2-hydroxyl-5-O-toluoyl-b-D-
ribofuranosyl)-2-iodo-N6-methyladenine (24)
The title compound was prepared as described for the
synthesis of 13 from 23 (200 mg, 0.335 mmol); yield:
127 mg (69%). 1H NMR (300 MHz, DMSO-d6): d 2.36
(s, 3H, CH3-Ph), 2.87 (d, 3H, J = 3.5 Hz, N
6-CH3),
4.29 (dd, J = 5.3 and 9.7 Hz, H4 0), 4.46–4.60 (m, 3H,
H3 0, H5 0A and H5 0B), 5.01 (t, 1H, J = 4.7 Hz, H2 0),
5.87 (d, 1H, J = 4.7 Hz, H1 0), 6.43 (d, 1H, J = 5.3 Hz,
2 0-OH), 7.29 (d, 2H, J = 8.2 Hz, Ph), 7.78 (d, 2H,
J = 8.2 Hz, Ph), 8.17 (d, 1H, J = 4.4 Hz, N6H), 8.21 (s,
1H, H8); Exact Mass (ESI-MS, i-PrOH/H2O): Calcd
for C19H20N8O4I [M+H]
+: 551.0653. Found: 551.0649.
4.25. 9-(3-Azido-3-deoxy-b-D-ribofuranosyl)-2-iodo-N6-
methyl-adenine (25)
Ester 24 (127 mg, 0.23 mmol) was dissolved in 2.5 mL
MeOH. Na (11.28 mg, 0.32 mmol) was added and the
mixture was stirred at room temperature for 1 h. The
reaction was quenched by adding a mixture of
CH3COOH/H2O (9:1, v/v) to pH 7. The solution was
concentrated to dryness, and the residue was puriﬁed
by column chromatography (CH2Cl2/MeOH, 98:2) to
yield 100 mg (95%) of compound 25. 1H NMR
(300 MHz, DMSO-d6): d 2.88 (d, 3H, J = 4 Hz, N
6-
CH3), 3.52–3.67 (m, 2H, H5
0A and H5 0B), 3.94 (dd,
1H, J = 7.26 and 3.81 Hz, H4 0), 4.28 (app t, 1H,
J = 4.5 Hz, H3 0), 4.89 (app t, 1H, J = 5.4 Hz, H2 0),
5.20 (br s, 1H, 5 0-OH), 5.80 (d, 1H, J = 6.16 Hz, H1 0),
6.25 (br s, 1H, 2 0-OH), 8.18 (d, 1H, J = 4 Hz, N6H),
8.28 (s, 1H, H8); Exact Mass (ESI-MS, i-PrOH/H2O):
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+: 433.0235. Found:
433.0237.
4.26. 9-(3-Azido-3-deoxy-5-O-toluoyl-b-D-ribofuranosyl)-
2-amino-N6-methyl-adenine (26)
Derivative 22 (100 mg, 0.21 mmol) was solubilized in
EtOH (5 mL). Methylammonium chloride (35 mg,
0.515 mmol) and Et3N (72 lL, 0.515 mmol) were added,
and the solution was reﬂuxed overnight. The mixture
was concentrated to dryness, the residue redissolved in
methanolic NH3 and the solution stirred at room temper-
ature for 2 h to allow deprotection of the 2 0-hydroxyl
group. Themixturewas concentrated to dryness and puri-
ﬁed on a silica gel column (CH2Cl2/MeOH, 97:3). Com-
pound 26 was obtained in 68% yield. 1H NMR
(300 MHz, DMSO-d6): d 2.36 (s, 3H, CH3-Ph), 2.84 (br
s, 3H, N6-CH3), 4.23 (dd, J = 5.27 and 9.38 Hz, H4
0),
4.43 (dd, 1H, J = 5.6 and 11.6, H5 0A), 4.55 (m, 2H,
H3 and H5 0B), 4.48 (app t, 1H, 4.7 Hz, H2 0), 5.78
(d, 1H, J = 4.7 Hz, H1 0), 5.95 (br s, 2H, 2-NH2), 6.34
(d, 1H, J = 7.9 Hz, 2 0-OH), 7.28 (br s, 1H, N6H), 7.29
(d, 2H, J = 7.9 Hz, Ph), 7.79 (s, 1H, H8), 7.82 (d, 2H,
J = 8.2 Hz, Ph); Exact Mass (ESI-MS, i-PrOH/H2O):
Calcd for C19H22N9O4 [M+H]
+: 440.1794. Found:
440.1789.
4.27. 9-(3-Azido-3-deoxy-b-D-ribofuranosyl)-2-amino-N6-
methyladenine (27)
The title compound was synthesized from 26 (60 mg,
0.013 mmol) by the procedure described for the synthe-
sis of 25; yield: 40 mg (91%). 1H NMR (300 MHz,
DMSO-d6): d 2.85 (br s, 3H, N
6-CH3), 3.48–3.64 (m,
2H, H5 0A and H5 0B), 3.89 (dd, 1H, J = 3.2 and
7.0 Hz, H4 0), 4.25 (dd, 1H, J = 3.2 and 5.6 Hz, H3 0),
4.88 (app t, 1H, J = 5.3 Hz, H2 0), 5.58 (t, J = 6.8 Hz,
1H, 5 0-OH), 5.71 (d, 1H, J = 6.2 Hz, H1 0), 5.85 (s, 2H,
NH2), 6.16 (s, 1H, 2
0-OH), 7.31 (br s, 1H, N6H), 7.89
(s, 1H, H8); Exact Mass (ESI-MS, i-PrOH/H2O): Calcd
for C11H16N9O3[M+H]
+: 322.1376. Found: 322.1365.
4.28. 9-[3-Azido-3-deoxy-5-(methylcarbamoyl)-b-D-
ribofuranosyl]-2-amino-6-chloropurine (28)
Derivative 11 (120 mg, 0.30 mmol)was dissolved inEtOH
(6 mL). Methylammonium chloride (30 mg, 0.46 mmol)
and Et3N (53 lL, 0.38 mmol) were added, and the solu-
tion was reﬂuxed overnight. The mixture was concentrat-
ed to dryness, the remaining solid dissolved in 7 NNH3 in
methanol and the solution stirred at room temperature
for 2 h to deprotect the 2 0-hydroxyl group. The mixture
was concentrated to dryness and the residue was puriﬁed
on a silica gel column (CH2Cl2/MeOH, 95:5). Compound
28 was obtained in 79% yield. 1H NMR (300 MHz,
DMSO-d6): d 2.68 (d, 3H, J = 4.7 Hz, CH3NHCO), 2.87
(s, 3H, N6-CH3), 4.24 (d, 1H, J = 2.9 Hz, H-4
0), 4.42
(dd, 1H, J = 2.9 and 5.3 Hz, H3 0), 4.97 (dd, 1H, J = 5.6
and 11.7 Hz, H2 0), 5.81 (d, 1H, J = 6.8 Hz, H1 0), 5.91 (s,
2H, NH2), 6.26 (d, 1H, J = 5.3 Hz, 2
0-OH), 7.31 (s, 1H,
N6H), 7.96 (s, 1H, H8), 8.35 (d, 1H, J = 4.7 Hz, NHCO);
Exact Mass (ESI-MS, i-PrOH/H2O): Calcd for
C12H17N10O3[M+H]
+: 349.1484. Found: 349.1491.4.29. Biological assays
4.29.1. Cell culture and membrane preparation. CHO cells
expressing recombinant human A3ARs were cultured in
DMEM (Dulbeccos modiﬁed Eagles medium) and F12
(1:1) supplemented with 10% foetal bovine serum,
100 U/mL penicillin, 100 lg/mL streptomycin, 2 lmol/
mL glutamine and 800 lL geneticin. After harvest and
homogenization, the cells were centrifuged at for
10 min. The pellet was resuspended in 50 mM Tris–HCl
buﬀer (pH 8.0) containing 10 mM MgCl2 and 1 mM
EDTA. The suspensionwas homogenized with an electric
homogenizer for 10 s and was then recentrifuged at
20,000g for 20 min at 4 C. The resulting pellets were
resuspended in buﬀer containing 3 U/mL of adenosine
deaminase, and the suspensionwas stored at80 Cprior
to the binding experiments. The protein concentration
was measured using the Bradford assay.25
4.29.2. Radioligand binding studies.For theA3ARbinding
experiments, the procedures were similar to those previ-
ously described.26 Brieﬂy, each tube contained 100 lL
of membrane suspension, 50 lL [125I]I-AB-MECA (ﬁnal
concentration 0.5 nM) and 50 lL of increasing concen-
trations of compounds in Tris–HCl buﬀer (50 mM, pH
7.4) containing 10 mM MgCl2, 1 mM EDTA. Non-spe-
ciﬁc binding was determined using 10 lM NECA. The
mixtures were incubated at 25 C for 60 min. Binding
reactions were terminated by ﬁltration throughWhatman
GF/B ﬁlters under reduced pressure using a MT-24 cell
harvester (Brandel, Gaithersburg, MD). Filters were
washed three times with ice-cold buﬀer. Radioactivity
was determined in aBeckman 5500B c-counter. The bind-
ing of [3H]R-PIA to the recombinant hA1AR and the
binding of [3H]CGS21680 to the recombinant hA2AAR
were performed as previously described.27,28
4.29.3. Cyclic AMP accumulation assay. Intracellular cyc-
lic AMP levels were measured by the competitive protein
bindingmethod.29 CHO cells expressing recombinant hu-
man30 ARs were harvested by trypsinization. After resus-
pension in the medium, cells were plated in 24-well plates
in 0.5 mL medium/well. After 24 h, the medium was re-
moved and cells were washed three times with 1 mL/well
DMEM containing 50 mM N-2-hydroxyethylpiper-
azine-N 0-2-ethanesulfonic acid, pH 7.4. Cells were then
treated with agonists and/or test compounds in the pres-
ence of rolipram (10 lM) and adenosine deaminase
(3 U/mL) and incubated at 37 C. For A3AR, after 45
min forskolin (10 lM) was added to the medium, and
incubation was continued for an additional 15 min. The
reaction was terminated upon removal of the medium,
and the cells were lysed with 200 lL/well of 0.1 M ice-cold
HCl. The cell lysate was resuspended and stored at
20 C. For determination of cyclic AMP production,
protein kinase A (PKA) was incubated with [3H]cyclic
AMP (2 nM) in K2HPO4/EDTA buﬀer (K2HPO4,
150 mM; EDTA, 10 mM), 20 lL of the cell lysate and
30 lL of 0.1 M HCl. Bound radioactivity was separated
by rapid ﬁltration through Whatman GF/C ﬁlters under
reduced pressure and washed once with cold buﬀer.
Bound radioactivity was subsequently measured by scin-
tillation spectrometry.
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